Background

Bariatric surgery is the gold standard of obesity treatment. However, weight recurrence (WR) remains an issue. We prospectively recruited participants with a history of Roux-en-Y Gastric Bypass (RYGB) up to ten years ago, with an average WR of 17.1% from nadir. The participants were randomized to either once daily Liraglutide 3.0 mg (Liraglutide) or placebo. We compared this with patients who had the gastric band-over bypass (GBOB) within 1-10 years of RYGB surgery. We recruited 89 people (14 males, 75 females) in the liraglutide with an average of 70.97 months after their primary surgery with a mean age of 46.74±9.74, and 43 (5 males, 38 females) in the placebo arm, with a mean of 63.90 months between their enrollment and RYGB, mean age 48.21±10.67. Data search identified 22 patients (7 males, 15 females) with a mean age of 46.35±9.23, had GBOB, with an average duration of 96.5 months between the two surgeries. Starting weight, post-op nadir weight, weight at the start of the intervention, and 1-year post-intervention weights (all in kg) for the liraglutide cohort were 136.42±32.44, 82.64±18.24, 100.75±20.46, 95.82 (8.7±8.0%), placebo, 128.85±19.71, 79.87±12.85, 96.32±14.36, 95.82 (0.6±4.4%), and GBOB, 155.77±41.21, 101.87±28.62, 126.78±27.9, 112.63±31.03 (12.5±9.7%), respectively. The weight loss observed after 1-year post-intervention was 8.7±8.0 in the liraglutide, 0.6±4.4% in the placebo group, and 12.5±9.7% in GBOB. RYGB is a crucial method to help lose weight. Long-term WR is still an issue with many patients. Both the GBOB procedure and liraglutide are effective in reducing weight recurrence. ClinicalTrials.gov Identifier: NCT03048578",,,,2023/06/27,Poster,ASMBS,Bariatric

Methods

Bypass

Results

Gastric

Conclusions

Laparoscopic